Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6252W HIGH $6.56
Volume
42.19 K
Value Traded
13.60 K
Short % Float
0.62%
Days to Cover
1.9
+5.26%Week
-6.74%1 Month
-16.86%3 Month
-13.88%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.63 M
EPS (TTM)
1.78
P/E Ratio
1.01
Ent. Value
4.75 M
Total Shares
7.02 M
Float Shares
3.31 M
Insiders
52.82%
Institutions
2.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
HIND Catalyst Timeline
Dated clinical, regulatory and corporate events for Vyome Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vyome Holdings, Inc.
164Total events
12Upcoming
44Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedVT-1908IP / Competition
USPTO issues Notice of Allowance for U.S. Patent Application No. 17/787,303 covering VT-1908 formulations and methods
ocular inflammatory diseasessource ↗
●Management ChangeCorporate
Jerry Leonard appointed Chief Financial Officer of Vyome Holdings
▲Patent GrantedIP / Competition
Chinese patent granted for immuno-inflammation portfolio
immuno-inflammationsource ↗
◆Oral PresentationVT-1953Presentation
Presentation of Phase 2 clinical data on VT-1953 for MFW at AACR 2026
MFWsource ↗
◆FDA Feedback ReceivedVT-1953FDA Meeting
Received FDA written response on proposed clinical development program
malignant fungating woundssource ↗
▲Partnership / LicenseCorporate
Signed agreement with Impetis to in-license two selective JAK inhibitor assets
autoimmune and inflammatory conditionssource ↗
▲Patent GrantedVB-1953IP / Competition
Granted Chinese patent covering formulation and therapeutic use claims for VB-1953
inflammatory acnesource ↗
●Pre IND MeetingVT-1953FDA Meeting
Submitted pre-IND briefing package to FDA for VT-1953
malignant fungating woundssource ↗
▲Preclinical PoCVT-1908Preclinical
Publication of positive preclinical results for VT-1908 in uveitis in peer-reviewed journal
uveitissource ↗
▲Primary Endpoint MetVT-1953Clinical Data
VT-1953 met primary endpoint of reducing malodor on Day 14 vs baseline (P=0.002) and vs vehicle (P=0.0015)
Malignant Fungating Wounds (MFW)source ↗
▲Secondary Endpoint DataVT-1953Clinical Data
VT-1953 met secondary endpoint of improving patient-reported impact of malodor on quality of life (P=0.0256 vs vehicle)
Malignant Fungating Wounds (MFW)source ↗
▲Biomarker DataVT-1953Clinical Data
VT-1953 showed significant improvement in exploratory endpoints: lesion pain (P=0.0026 vs vehicle) and QoL (P=0.0032 vs vehicle)
Malignant Fungating Wounds (MFW)source ↗
●Orphan Drug DesignationVT-1953Designation
Orphan drug designation application filed for VT-1953
Malignant Fungating Wounds (MFW)source ↗
◆FDA Feedback ReceivedVT-1953FDA Meeting
Discussions with FDA on Phase 3 design ongoing
Malignant Fungating Wounds (MFW)source ↗
◆Orphan Drug DesignationVT-1953Designation
Filed for Orphan Drug Status for VT-1953
malignant fungating wounds (MFW)source ↗
▲PublicationVT-1908Presentation
Preclinical results for topical mycophenolate (VT-1908) published in Journal of Ophthalmic Inflammation and Infection
uveitis-associated inflammationsource ↗
▲Preclinical PoCVT-1908Preclinical
Topical mycophenolate demonstrated steroid-comparable efficacy in preclinical uveitis model
uveitissource ↗
▲Quarterly UpdateCorporate
Independent analyst values VT-1953 at USD 1 billion upon successful Phase 3 completion
▲Oral PresentationVT-1953Presentation
Presented Phase 2 clinical data at AACR
malignant fungating woundssource ↗
▲Patent GrantedVB-1953IP / Competition
Received granted Chinese patent for VB-1953 topical gel
inflammatory acnesource ↗
◆Full ResultsVT-1953Clinical Data
Full Phase 2 data readout expected
malignant fungating wounds (MFW)source ↗
▲Interim AnalysisVT-1953Trial
Interim Phase 2 results for VT-1953 announced
malignant fungating wounds (MFW)source ↗
◆FDA Feedback ReceivedVT-1953FDA Meeting
Planning discussions with FDA on pivotal trial protocol
Malignant Fungating woundssource ↗
◆FDA Feedback ReceivedFDA Meeting
Pivotal trial protocol approved by FDA
Malignant Fungating Woundsource ↗
▲First Patient DosedTrial
First patient recruitment for pivotal study
Malignant Fungating Woundsource ↗
▲Preclinical PoCVT-1908Preclinical
Preclinical efficacy for VT-1908 eye drops in uveitis models reported
uveitissource ↗
◆FDA Feedback ReceivedVT-1953FDA Meeting
Planned discussions with FDA on pivotal trial protocol for VT-1953
Malignant Fungating woundssource ↗
▼Equity OfferingCorporate
Pricing of $2.6 million public offering of 1,054,604 shares at $2.50 per share
▲First Patient DosedTrial
First patient recruitment for pivotal study
Malignant Fungating Woundsource ↗
Past FDA Catalysts and PDUFA Decisions
How HIND actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every HIND program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VT - 1953 Orphan | malignant fungating wounds | Phase 2 | 2026-02-13 | significant improvement (P=0.002) in the primary endpoint of malodor on Day 14 vs baseline; statistically significant (P=0.0015) compared with vehicle-treated patients; significant improvement (P=0.0256) in the secondary endpoint of patient-reported impact of malodor on the quality of life compared to vehicle-treatment by Day 14; clinically significant improvement in lesion pain symptoms (P=0.002 compared with baseline; P=0.0026 vs vehicle-treated patients)Read More | VT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS Vyome Holdings, Inc. February 2026 VYOME HOLDINGS, INC. ("Vyome") 2 Any statements contained in this presentation Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| STANKOVICH THOMASOfficer (Chief Financial Officer) | Sell | -48 22,777 held | $0.25 | 05/31/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in HIND
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HIND for Q2 2026. | ||||
Ownership Trends
HIND Short Interest
Shares sold short, counted twice a month.
0.62%
Short % of Float
of tradable shares sold short
20.7K
Shares Sold Short
-21.2% vs prior count
1.9 Low
Days to Cover
trading days of normal volume to buy every short share back
10.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HIND ranks across every disease it competes in
Competitive Position is a premium feature
See how HIND ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHIND News
HINDVyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
Vyome Holdings announced that Dr. Shiladitya Sengupta has been promoted to Professor of Medicine at Harvard Medical School. This recognition reflects his extensive contributions to biomedical research and drug discovery. Dr. Sengupta's work has significantly influenced Vyome's approach to addressing unmet medical needs, particularly in oncology and inflammation.
Read more →HINDVyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
Vyome Holdings has received a Notice of Allowance from the USPTO for its patent application covering VT-1908, a topical formulation aimed at treating ocular inflammatory diseases. The formulation has demonstrated efficacy comparable to steroids in preclinical trials for uveitis. The company sees significant market potential exceeding $20 billion for ocular inflammation treatments.
Read more →HINDVyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
Vyome Holdings, Inc. has appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026. Leonard brings over 25 years of financial management experience and will oversee the company's financial operations and governance. His appointment is expected to strengthen Vyome's financial processes as the company advances its development programs.
Read more →HINDVyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
Vyome Holdings reported its second quarter 2026 results, highlighting the advancement of its lead program, VT-1953, which showed significant improvements in clinical trials. The company also expanded its pipeline through a partnership with Impetis and maintained a strong financial position with no debt. However, it reported a net loss and is awaiting further FDA feedback to advance its clinical programs.
Read more →HINDVyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
Vyome has been granted a patent in China, which enhances its immuno-inflammation portfolio. This development is expected to strengthen the company's position in the market. Further details on the implications of this patent grant were not disclosed in the article.
Read more →HINDVyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings has reported its financial results for the first quarter of 2026, highlighting key FDA filings and a robust balance sheet. The report indicates the company's ongoing efforts to strengthen its position in the biopharma sector. Further details on the specific FDA filings and financial metrics were not disclosed in the article.
Read more →HINDVyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome Pharmaceuticals has entered into a strategic partnership with Impetis Biosciences. This collaboration aims to explore opportunities in a market estimated to be worth approximately $57 billion. The deal is expected to enhance Vyome's position in the biopharma sector, although specific details about the partnership's terms have not been disclosed.
Read more →HINDVyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Vyome Holdings presented promising Phase 2 clinical study results for VT-1953 at the AACR 2026. The topical gel showed significant efficacy in reducing severe malodor and pain associated with malignant fungating wounds (MFW). Notably, 70% of patients reported improved quality of life, and no adverse effects were observed. These findings support further development of VT-1953 as a treatment option for MFW symptoms.
Read more →HINDVyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome is set to present Phase 2 clinical data on VT-1953 for the treatment of MFW at the AACR 2026 conference. This presentation highlights the company's ongoing research efforts in this area. Details regarding the specific findings or implications of the data have not been disclosed.
Read more →HINDVyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Holdings, Inc. reported positive financial results and clinical milestones following its Nasdaq listing. The company achieved encouraging final Phase 2 results for VT-1953, a treatment for malignant fungating wounds, and received a valuation of approximately $1 billion. With a strong cash position and new leadership, Vyome is well-positioned for future growth.
Read more →HIND▲ +8.3%on this news· ran to +20% by day 1
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Livechain, a subsidiary of Vyome Holdings, has acquired Humanyze, an AI-enabled HR analytics company, through a debt purchase agreement. This all-stock transaction, valued at approximately $325,000, allows Livechain to take control of Humanyze's operations and assets. The acquisition aims to enhance Livechain's position in the AI HR sector and potentially lead to an uplisting on a national exchange.
Read more →HIND▲ +6.8%on this news
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Holdings, Inc. announced positive preclinical results for VT-1908, a potential treatment for uveitis, published in the Journal of Ophthalmic Inflammation and Infection. The study demonstrated that VT-1908 effectively reduced uveitis scores without toxicity, positioning it as a viable alternative to traditional steroids. The company aims to advance VT-1908 into clinical development, targeting a significant market opportunity.
Read more →HINDVT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS Vyome Holdings, Inc. February 2026
Vyome Holdings, Inc. has announced promising results from the Phase 2 study of VT - 1953 for treating malignant fungating wounds (MFW). The study demonstrated significant improvements in the primary endpoint of malodor and secondary endpoints related to quality of life and lesion pain. Specifically, patients treated with VT - 1953 reported marked enhancements in symptom relief compared to those receiving a vehicle treatment. The results provide a foundation for continued clinical exploration of VT - 1953 as a viable treatment option for MFW.
Read more →HINDVyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Holdings has filed for Orphan Drug Status for its lead program VT-1953, which targets malignant fungating wounds (MFW) affecting advanced cancer patients. The company reported positive Phase 2 results and anticipates significant market potential, with a projected U.S. asset value of $455 million. Vyome aims to advance this program strategically over the next six months.
Read more →HIND▲ +14.6%on this news
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Vyome Holdings has successfully secured funding for its VT-1953 Phase 3 study, ensuring capital for interim results expected in mid-2027. The company utilized its At-The-Market facility, achieving this with minimal dilution. Management emphasized their commitment to shareholder value and noted the drug's potential worth of $1 billion upon trial completion.
Read more →HIND▼ -22.1%on this news· ran to -34% by day 1shared move
U.S. Market & Product Assessment and Valuation of VT - 1953 for the Treatment of Symptoms of Malignant Fungating Wounds H1 2026 2 PROJECT OVERVIEW Destum Partners performed a U.S. market and product assessment, commercia
Destum Partners has completed a U.S. market and product assessment for VT - 1953, a potential treatment for malignant fungating wounds (MFW). This condition is a severe complication of advanced solid tumors, often resulting in significant patient suffering and high unmet need. Currently, no FDA-approved therapies target MFW symptoms, creating an opportunity for VT - 1953 to fill this gap. The assessment projects that VT - 1953 will achieve a rNPV valuation of $455 million in the U.S. as of H1 2026, with expectations for growth to $1.086 billion by H1 2028 upon completing Phase 3 trials.
Read more →HINDIndependent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome Holdings announced a valuation analysis for its lead candidate VT-1953, aimed at treating malignant fungating wounds. Conducted by Destum Partners, the assessment suggests a potential market value of USD 1 billion following successful Phase 3 trials. The analysis highlights a significant unmet need in oncology supportive care, with estimated peak sales of USD 600 million.
Read more →HIND▲ +5.4%on this news
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Vyome Holdings' subsidiary, LiveChain, has signed a letter of intent to acquire a senior secured note from Humanyze, an AI-driven HR analytics company. The deal, valued at approximately $325,000 in stock, positions LiveChain as Humanyze's senior secured creditor. This acquisition aims to enhance LiveChain's financial independence and create value for shareholders, although the transaction is subject to final agreements.
Read more →HIND▼ -7.2%on this news
Vyome Holdings Announces Transformational First Following Nasdaq Listing
Vyome Holdings, Inc. reported strong financial results for the quarter ended September 30, 2025, following its successful Nasdaq listing. Highlights included positive interim data for the VT-1953 drug targeting malignant fungating wounds (MFW), a significant unmet medical need. The company emphasized its efficient transition to public markets with a clean capital structure, while facing substantial operating losses. CEO Venkat Nelabhotla expressed confidence in the potential of their immuno-inflammation platform to drive long-term value for shareholders and patients.
Read more →HINDVyome Holdings Acquires MIT AI Spinout Oculo Health Launches business unit to create AI psychiatrist focused on reducing
Vyome Holdings has acquired Oculo, an AI startup from MIT, and launched a new division focused on developing an AI psychiatrist aimed at reducing inflammation. This initiative targets behavioral drivers and biomarkers related to inflammation, anticipating a market growth potential exceeding $100 billion in digital therapeutics. The acquisition will not affect the progression of Vyome's core biotech assets, as the company remains fully funded through 2026. Their goal is to create a new therapeutic category combining mental health and digital health solutions.
Read more →About Vyome Holdings, Inc.
Headquarters1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
BIOPHARMAWATCH ELITE PLUS
Trade the next HIND catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime